NeuroPace, Inc. revised earnings guidance for the full year 2023. For the year, the company Increased total revenue guidance to range between $59 million and $61 million, representing growth of 30% to 34% over 2022, as compared to prior guidance of between $52 million and $54 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.91 USD | +5.66% | -8.23% | -32.98% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.98% | 20Cr | |
+7.01% | 22TCr | |
+11.01% | 19TCr | |
+19.20% | 14TCr | |
+30.79% | 11TCr | |
+1.48% | 6.46TCr | |
+13.95% | 5.24TCr | |
-0.16% | 4.85TCr | |
-6.20% | 3.8TCr | |
+0.91% | 3.56TCr |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023